The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Over the last 7 days, the United States market has dropped 1.6%, yet it remains up by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic ...

As of now, Halozyme’s stock has delivered a YTD performance of +36.82%, outpacing the S&P 500’s +19.62% return. This stark contrast not only showcases Halozyme’s exceptional growth but also emphasizes ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Granted, Ocrevus Zunovo is a very large volume subcutaneous version of the drug that requires 10 minutes to administer, and the whole process takes about 55 minutes after the first dose ...

After that, it's given in 600-milligram (mg) doses once every six months. Ocrevus Zunovo (ocrelizumab and hyaluronidase) was approved in 2024 to treat PPMS. The recommended dose is 920 mg/23,000 units ...

Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...

FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug manufacturer Catalent, opens new tab by Novo Nordisk's controlling ...

Roche is looking to use Dyno’s technologies to target neurological diseases, a big focus at the Swiss pharma, with multiple sclerosis blockbuster Ocrevus serving as its best-selling asset.